GILBERTSVILLE, Pa. – Rockland Immunochemicals (www.rockland-inc.com) has produced a new Anti-NF-?B monoclonal antibody (catalog number 200-301-065) validated by several assays relevant for discovery including immunofluorescence microscopy (IF), immunohistochemistry (IHC), western blotting (WB) and ELISA (E).

The NF-?B p65 antibody was produced by using our electrofusion hybridoma technology. NF-?B is located in the cytosol complexed with the inhibitory protein I?B?. In response to extracellular stimuli the inhibitory molecule is marked for degradation releasing NF-?B which then translocates to the nucleus and binds to target gene sequences. NF-?B has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. NF-?B is a key target for drug discovery. Aberrant activation of NF-?B is frequently observed in many cancers.

Rockland is excited about the commercial success of its monoclonal Anti-NF-?B p65 (Rel A) antibody. This antibody will enhance our existing portfolio of reagents that investigate NF-?B Signaling.

Rockland produces other NF-?B antibodies including Anti-IKB?and Anti-NF-?B p65 pS276.

About Rockland Immunochemicals.

Rockland Immunochemicals has supported the biopharma and diagnostic industries for over 40 years with antibodies and antibody based tools™ for basic research, assay development, and preclinical studies. With manufacturing facilities in Pennsylvania, Rockland produces antibodies for western blotting, immunohistochemistry (IHC), immunofluorescence microscopy, ELISA and FLOW cytometry. More information about Rockland Immunochemicals and their products and services can be found at the company’s web site at www.rockland-inc.com.